Literature DB >> 25529143

Fasciola hepatica: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology.

R E B Hanna1, C McMahon2, S Ellison3, H W Edgar2, P-E Kajugu2, A Gordon4, D Irwin5, J P Barley2, F E Malone2, G P Brennan3, I Fairweather3.   

Abstract

In order to investigate the incidence and distribution of adult fluke resistance to the fasciolicide tricalbendazole (TCBZ) amongst populations of Fasciola hepatica in sheep flocks in Northern Ireland (NI), individual rectal faeces samples were collected from 3 groups of 20 sheep, before (pre-dose), and 21 days after (post-dose) treatment of the animals with TCBZ, nitroxynil or closantel, on each of 13 well-managed sheep farms distributed across the province. The efficacy of each flukicide was determined for each farm, using faecal egg count reduction (FECRT) and F. hepatica coproantigen ELISA testing. In certain flocks, 2 sheep with high pre-dose faecal egg counts (FEC) were killed 3 days and 21 days respectively after TCBZ treatment, and the histology of the fluke reproductive organs was compared with that of flukes from untreated sheep, and from sheep treated with nitroxynil or closantel 2 days prior to death, using haematoxylin and eosin (H&E) staining and an in situ hybridisation method (TdT-mediated dUDP nick end labelling [TUNEL]) to demonstrate apoptosis. Results from FECRT revealed that in all flocks with a high fluke burden, TCBZ was ineffective in treating chronic fasciolosis, and this finding was generally supported by the results of the coproantigen reduction test (CRT). The histology of reproductive organs of flukes from TCBZ-treated sheep in these flocks was normal, when compared with untreated flukes, and this, together with the FECRT and CRT findings, indicated a likely diagnosis of TCBZ resistance in all the flocks with a high fluke burden. In contrast, nitroxynil and closantel were found to be fully effective against TCBZ-resistant flukes in each of the flocks bearing a high chronic fluke burden. All of the flocks with a high fluke burden and TCBZ resistance were managed on lowland in the South and East of NI. Upland flocks, in the North and West, had low fluke burdens, or were clear of infection; and FECs were too low to allow valid resistance testing. The study highlights the high level of penetration of TCBZ resistance throughout F. hepatica populations in areas of intensively managed sheep production with a high level of fluke challenge. Further, it emphasises the importance of pre-emptive chemotherapeutic action against chronic fasciolosis, using flukicides effective against the egg-producing adult flukes to minimise pasture contamination for the next season's lamb crop. This study also exemplifies the use of several complementary methods (FECRT; CRT; fluke histology; comparative anthelmintic efficacy testing) for confirmation of a diagnosis of fluke drug resistance.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coproantigen ELISA reduction test; Faecal egg count reduction test; Fasciola hepatica; Histology; Nitroxynil and closantel; Triclabendazole resistance

Mesh:

Substances:

Year:  2014        PMID: 25529143     DOI: 10.1016/j.vetpar.2014.11.016

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  19 in total

1.  Field study on the determination of the effective dose of injectable fosfatriclaben prodrug in sheep naturally infected with Fasciola hepatica.

Authors:  Froylán Ibarra-Velarde; Tania Rojas-Campos; Yolanda Vera-Montenegro; Miguel Flores-Ramos; Rafael Castillo; Gerardo Leyva-Gómez
Journal:  Parasitol Res       Date:  2021-11-05       Impact factor: 2.289

Review 2.  Fasciolosis-An Increasing Challenge in the Sheep Industry.

Authors:  Snorre Stuen; Cecilie Ersdal
Journal:  Animals (Basel)       Date:  2022-06-08       Impact factor: 3.231

Review 3.  Fasciola hepatica: Histology of the Reproductive Organs and Differential Effects of Triclabendazole on Drug-Sensitive and Drug-Resistant Fluke Isolates and on Flukes from Selected Field Cases.

Authors:  Robert Hanna
Journal:  Pathogens       Date:  2015-06-26

4.  Rapid Enhanced MM3-COPRO ELISA for Detection of Fasciola Coproantigens.

Authors:  Victoria Martínez-Sernández; Ricardo A Orbegozo-Medina; Marta González-Warleta; Mercedes Mezo; Florencio M Ubeira
Journal:  PLoS Negl Trop Dis       Date:  2016-07-20

5.  Anthelmintic Potential of Thymoquinone and Curcumin on Fasciola gigantica.

Authors:  Rizwan Ullah; Abdur Rehman; Mohd Faraz Zafeer; Lubna Rehman; Yasir A Khan; M A Hannan Khan; Shahper N Khan; Asad U Khan; S M A Abidi
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

6.  First report of closantel treatment failure against Fasciola hepatica in cattle.

Authors:  Adam Novobilský; Johan Höglund
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-08-28       Impact factor: 4.077

7.  Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test.

Authors:  Adam Novobilský; Natalia Amaya Solis; Moa Skarin; Johan Höglund
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-06-26       Impact factor: 4.077

8.  Fasciola hepatica demonstrates high levels of genetic diversity, a lack of population structure and high gene flow: possible implications for drug resistance.

Authors:  Nicola J Beesley; Diana J L Williams; Steve Paterson; Jane Hodgkinson
Journal:  Int J Parasitol       Date:  2016-12-07       Impact factor: 3.981

9.  Development and validation of a protocol to identify and recruit participants into a large scale study on liver fluke in cattle.

Authors:  Catherine M McCann; Helen E Clough; Matthew Baylis; Diana J L Williams
Journal:  BMC Vet Res       Date:  2018-06-15       Impact factor: 2.741

Review 10.  Fasciola and fasciolosis in ruminants in Europe: Identifying research needs.

Authors:  N J Beesley; C Caminade; J Charlier; R J Flynn; J E Hodgkinson; A Martinez-Moreno; M Martinez-Valladares; J Perez; L Rinaldi; D J L Williams
Journal:  Transbound Emerg Dis       Date:  2017-10-06       Impact factor: 5.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.